568 reports of this reaction
1.8% of all FEBUXOSTAT reports
#10 most reported adverse reaction
ANAEMIA is the #10 most commonly reported adverse reaction for FEBUXOSTAT, manufactured by Takeda Pharmaceuticals America, Inc.. There are 568 FDA adverse event reports linking FEBUXOSTAT to ANAEMIA. This represents approximately 1.8% of all 31,059 adverse event reports for this drug.
Patients taking FEBUXOSTAT who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for FEBUXOSTAT, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for FEBUXOSTAT:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 568 FDA reports for FEBUXOSTAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 1.8% of all adverse event reports for FEBUXOSTAT, making it a notable side effect.
If you experience anaemia while taking FEBUXOSTAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.